Breaking Down Xeris Biopharma Holdings, Inc. (XERS) Financial Health: Key Insights for Investors

Are you keeping a close watch on your investments in the biopharmaceutical sector? With Xeris Biopharma Holdings, Inc. (XERS) making waves, it's time to dive deep into their financial health. Did you know that Xeris reported a record total revenue of $203 million for the full year 2024, exceeding their previous guidance of $198 million to $202 million? Furthermore, the company ended 2024 with over $71 million in cash, cash equivalents, and short-term investments, showcasing a strong financial position. How did key products like Recorlev, Gvoke, and Keveyis perform, and what impact did they have on the overall financial results? Read on to explore these key insights and more, helping you make informed decisions about Xeris Biopharma.

Xeris Biopharma Holdings, Inc. (XERS) Revenue Analysis

Understanding the revenue streams of Xeris Biopharma Holdings, Inc. (XERS) is crucial for investors seeking to assess the company's financial health and growth potential. A detailed look into the sources, growth rates, and segment contributions provides a comprehensive view of the company's financial performance.

Xeris Biopharma focuses on developing and commercializing innovative therapies in endocrinology, neurology, and gastroenterology. Their primary revenue streams are derived from:

• Product Sales: Revenue generated from sales of their commercialized products, such as Gvoke (glucagon injection) for severe hypoglycemia.
• Licensing and Collaboration Agreements: Income from partnerships with other pharmaceutical companies, including upfront payments, milestone payments, and royalties on partnered products.

Analyzing the year-over-year revenue growth rate provides insights into Xeris Biopharma's performance trajectory. According to the 2024 financial results, Xeris Biopharma Holdings, Inc. reported total revenues of $146.1 million, representing a 27% increase compared to $114.8 million in the prior year. This growth was primarily driven by an increase in net product revenue.

Here's a breakdown of the revenue streams based on the latest available information:

Net Product Revenue:

• For the year 2024, net product revenue was $143.2 million, up from $109.1 million in 2023.
• This increase is mainly attributable to higher sales volumes of Gvoke.

License and Collaboration Revenue:

• License and collaboration revenue increased to $2.9 million in 2024 from $5.7 million in 2023.

The following table summarizes Xeris Biopharma's revenue streams for 2024:

Significant fluctuations in revenue streams can be attributed to various factors, such as:

• Market Dynamics: Changes in market demand for their products.
• Regulatory Approvals: Approval of new products or indications can significantly boost revenue.
• Partnerships: New or modified collaboration agreements can impact licensing and royalty revenues.
• Competition: The entry of new competitors or the introduction of competing products.

For further insights into the company's strategic direction, see Mission Statement, Vision, & Core Values of Xeris Biopharma Holdings, Inc. (XERS).

Xeris Biopharma Holdings, Inc. (XERS) Profitability Metrics

A closer examination of Xeris Biopharma Holdings, Inc. (XERS) reveals several key insights into its profitability. Understanding these metrics is crucial for investors seeking to assess the company's financial health and future prospects. For the fiscal year ended December 31, 2024, Xeris Biopharma reported a revenue of $203 million.

Here's a breakdown of the company's profitability metrics:

• Gross Profit: Xeris Biopharma's gross profit for 2024 was $166.24 million.
• Gross Profit Margin: In 2024, the gross profit margin stood at 81.86%.
• Operating Margin: The annual operating margin trends ending December 31, 2024 are available.
• EBIT Margin: The EBIT (Earnings Before Interest and Taxes) margin was -13.56%.
• Net Loss: The net loss for 2024 was $54.8 million, equating to a loss of $0.37 per share.
• Net Profit Margin: The net profit margin was -27.0%.

While Xeris Biopharma is currently unprofitable, its revenue has been growing. The company's CEO, John Shannon, noted that Xeris had an exceptional 2024 with record revenue topping $203 million. The company is focused on driving product revenue growth and advancing its pipeline. For a deeper understanding of Xeris Biopharma's values, explore Mission Statement, Vision, & Core Values of Xeris Biopharma Holdings, Inc. (XERS).

Here's a summary of Xeris Biopharma's financial performance in 2024:

• Total Revenue: $203 million, a 23.9% increase from $163.9 million in 2023.
• Net Loss: $54.8 million ($0.37 per share), compared to a net loss of $62.3 million ($0.45 per share) in 2023.

The company's financial results reflect growth in key areas, alongside ongoing investments in research and development. Research and development expenses for the year ended December 31, 2024, increased by $3.2 million, or 14%, compared to the same period in 2023. This increase was primarily due to higher personnel-related expenses and increased spending for their pipeline.

Cost of goods sold (COGS) also increased by $8.2 million, or 29%, for the year ended December 31, 2024, compared to the same period in 2023. This increase was attributed to increased product revenue ($4.9 million) and additional inventory reserves from process changes required for Gvoke capacity expansion ($4.5 million), offset by lower reserves for slow-moving inventory.

Selling, general, and administrative (SG&A) expenses increased by $17.4 million, or 12%, for the year ended December 31, 2024, compared to the same period in 2023. This increase was primarily due to incremental investment in the Recorlev commercial organization.

A detailed look at revenue from specific products reveals:

• Recorlev: Net revenue was $64.3 million for the year ended December 31, 2024, an increase of approximately 118% compared to the prior year.
• Keveyis: Net revenue was $49.5 million for the year ended December 31, 2024, a decrease of approximately 13% compared to the prior year.

Xeris Biopharma is strategically investing in its pipeline and commercial operations, which is reflected in the increased R&D and SG&A expenses. While the company is currently operating at a net loss, the growth in revenue and positive adjusted EBITDA suggest a potential path to future profitability. The company anticipates total revenue for 2025 to be in the range of $255 million to $275 million, representing over 30% growth at the mid-point.

Xeris Biopharma Holdings, Inc. (XERS) Debt vs. Equity Structure

Understanding how Xeris Biopharma Holdings, Inc. (XERS) manages its debt and equity is crucial for investors assessing the company's financial health and growth potential. This involves analyzing the levels of debt, the balance between debt and equity financing, and any recent financing activities.

As of the fiscal year 2024, a comprehensive picture of Xeris Biopharma Holdings, Inc.'s debt levels is essential. While specific figures for 2024 are not available, examining previous years provides a valuable context. For instance, information regarding long-term and short-term debt from earlier financial reports can offer insights into the company's debt management strategy. Investors should seek the most recent financial filings to obtain the most accurate and up-to-date figures.

The debt-to-equity ratio is a key metric in evaluating Xeris Biopharma Holdings, Inc.'s financial leverage. This ratio indicates the proportion of debt the company uses to finance its assets relative to the value of shareholders' equity. A high ratio suggests a more aggressive financing strategy, which could increase financial risk. The specific debt-to-equity ratio for Xeris Biopharma Holdings, Inc. should be compared against industry averages to determine whether it is within a reasonable range.

Recent activities, such as debt issuances, credit ratings, or refinancing, significantly impact Xeris Biopharma Holdings, Inc.'s financial position. Any new debt can provide the company with additional capital for investments but also increases its debt obligations. Credit ratings from agencies like Moody's or Standard & Poor's reflect the creditworthiness of Xeris Biopharma Holdings, Inc., influencing the interest rates it pays on its debt. Refinancing activities can help the company lower its interest expenses or extend the maturity of its debt.

Balancing debt and equity financing is critical for Xeris Biopharma Holdings, Inc.'s long-term sustainability. While debt financing can provide a cost-effective way to fund growth, excessive debt can strain the company's cash flow and increase the risk of financial distress. Equity funding, on the other hand, dilutes ownership but strengthens the balance sheet. The company's approach to balancing these two forms of financing reflects its strategic priorities and risk tolerance.

For more insights into the company's values, see: Mission Statement, Vision, & Core Values of Xeris Biopharma Holdings, Inc. (XERS).

Xeris Biopharma Holdings, Inc. (XERS) Liquidity and Solvency

Liquidity and solvency are crucial indicators of a company's financial health, revealing its ability to meet short-term obligations and sustain long-term operations. For Xeris Biopharma Holdings, Inc. (XERS), assessing these metrics provides insights into its financial stability and operational efficiency.

Assessing Xeris Biopharma Holdings, Inc.'s Liquidity:

Analyzing Xeris Biopharma's liquidity involves examining key ratios and cash flow trends to gauge its ability to cover short-term liabilities.

• Current and Quick Ratios: These ratios measure a company's ability to pay off its current liabilities with its current assets. The current ratio is calculated by dividing current assets by current liabilities, while the quick ratio excludes inventory from current assets to provide a more conservative measure.
• Analysis of Working Capital Trends: Working capital, calculated as current assets minus current liabilities, indicates a company's operational liquidity. Monitoring trends in working capital helps identify whether Xeris Biopharma is efficiently managing its short-term assets and liabilities.
• Cash Flow Statements Overview:

Cash flow statements are vital for understanding the movement of cash both into and out of a company. They are generally divided into three main activities:

• Operating Activities: This reflects the cash generated from the company's core business operations. A positive trend indicates the company is effectively generating cash from its products or services.
• Investing Activities: This includes cash flow related to the purchase and sale of long-term assets, such as property, plant, and equipment (PP&E).
• Financing Activities: This involves cash flow related to debt, equity, and dividends. Monitoring these activities can reveal how the company is funding its operations and managing its capital structure.

Potential liquidity concerns or strengths can be identified by analyzing these cash flow trends, providing a comprehensive view of Xeris Biopharma's financial stability. For instance, consistent positive cash flow from operations indicates a strong ability to fund its activities, while negative trends may signal the need for external financing or operational adjustments.

Here you can find more information about Xeris Biopharma Holdings, Inc. (XERS) Financial Health: Breaking Down Xeris Biopharma Holdings, Inc. (XERS) Financial Health: Key Insights for Investors

Xeris Biopharma Holdings, Inc. (XERS) Valuation Analysis

Determining whether Xeris Biopharma Holdings, Inc. (XERS) is overvalued or undervalued requires a multifaceted approach, incorporating key financial ratios, stock performance analysis, and analyst sentiment. Here’s a breakdown of essential valuation metrics:

Price-to-Earnings (P/E) Ratio: As Xeris Biopharma Holdings, Inc. (XERS) does not currently have positive earnings, the P/E ratio is not applicable for its valuation.

Price-to-Book (P/B) Ratio: The P/B ratio compares a company's market capitalization to its book value of equity. As of 2024, Xeris Biopharma's P/B ratio is approximately 2.97. This indicates how much investors are willing to pay for each dollar of the company's net assets.

Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: The EV/EBITDA ratio is used to assess the overall value of a company relative to its earnings before interest, taxes, depreciation, and amortization. For Xeris Biopharma, the current EV/EBITDA ratio is -12.12. A negative ratio suggests that the company's EBITDA is negative, which can occur when a company is not yet profitable or is experiencing financial difficulties.

Stock Price Trends: Over the past year, Xeris Biopharma Holdings, Inc. (XERS) has shown significant stock price volatility. As of April 2025, the stock is trading at $3.41. The stock has fluctuated, reflecting broader market trends and company-specific developments. Monitoring these trends is crucial for understanding market sentiment and potential investment opportunities.

Dividend Yield and Payout Ratios: Currently, Xeris Biopharma Holdings, Inc. (XERS) does not offer a dividend. Therefore, dividend yield and payout ratios are not applicable.

Analyst Consensus: Analyst ratings provide insights into the perceived valuation of Xeris Biopharma Holdings, Inc. (XERS). According to the latest consensus, the stock is rated as a 'Moderate Buy'. Price targets from analysts range from a low of $6.00 to a high of $10.00, with an average target price of $8.00. This suggests analysts anticipate potential upside from the current trading price.

Here is a summary of the analyst ratings:

• Buy: 3
• Hold: 3
• Sell: 0

These ratings reflect a generally positive outlook, with analysts believing the stock has the potential to increase in value.

Here is a detailed financial ratios data for Xeris Biopharma Holdings, Inc. (XERS):

For further insights, you can explore: Breaking Down Xeris Biopharma Holdings, Inc. (XERS) Financial Health: Key Insights for Investors

Xeris Biopharma Holdings, Inc. (XERS) Risk Factors

Several internal and external factors can significantly impact Xeris Biopharma Holdings, Inc. (XERS)'s financial health. These risks span from industry competition and regulatory changes to market conditions, and are crucial for investors to consider.

Industry Competition: The pharmaceutical industry is intensely competitive. Xeris faces competition from established pharmaceutical companies, generic drug manufacturers, and biotechnology firms. These competitors may have greater financial, research, and marketing resources. Intense competition could lead to price erosion, reduced market share, and decreased profitability for Xeris.

Regulatory Changes: The development, manufacturing, and marketing of pharmaceutical products are subject to extensive regulation by government authorities, including the FDA in the United States and similar bodies in other countries. Changes in regulations or the introduction of new legislation could increase the cost and time needed to bring new products to market, impacting Xeris's financial performance. For instance, stricter approval processes or changes in patent laws could adversely affect revenue streams.

Market Conditions: Economic downturns, changes in healthcare policies, and shifts in market demand can all influence Xeris's financial stability. Reduced healthcare spending or unfavorable reimbursement policies by insurance companies can limit the adoption of Xeris's products, affecting sales and profitability.

Operational Risks: These include challenges related to manufacturing, supply chain disruptions, and product recalls. Any disruption in the production or supply of Xeris’s products can lead to revenue losses and increased costs. Maintaining product quality and safety is also critical; any product recalls or safety concerns can damage the company’s reputation and lead to legal liabilities.

Financial Risks: Xeris needs to manage its cash flow effectively to fund its operations, research and development, and commercialization activities. Factors such as debt levels, interest rates, and access to capital markets can impact its financial flexibility. If Xeris cannot secure additional funding when needed, it may have to delay or scale back its strategic initiatives.

Strategic Risks: These encompass risks associated with Xeris's business strategy, such as the success of new product launches, the effectiveness of its marketing efforts, and its ability to form strategic partnerships. Delays in launching new products or failure to gain market acceptance can negatively impact revenue projections. Additionally, the failure to establish or maintain key partnerships could limit Xeris's growth opportunities.

Mitigation strategies often include diversifying product portfolios, strengthening intellectual property protection, implementing robust risk management systems, and maintaining strong relationships with regulatory bodies. However, the effectiveness of these strategies can vary, and there is no guarantee that Xeris will successfully navigate all the risks it faces.

More in-depth analysis can be found here: Breaking Down Xeris Biopharma Holdings, Inc. (XERS) Financial Health: Key Insights for Investors

Xeris Biopharma Holdings, Inc. (XERS) Growth Opportunities

Xeris Biopharma Holdings, Inc. (XERS) is poised for future growth, driven by several key factors. These include product innovations, strategic market expansions, potential acquisitions, and advantageous partnerships.

Product innovation remains a cornerstone of Xeris Biopharma's growth strategy. The company's focus on developing and commercializing ready-to-use injectable and infusible drug formulations offers a distinct advantage. For instance, their XeriJect™ technology platform is designed to improve the patient experience by eliminating the need for reconstitution, which can be particularly beneficial for patients with chronic conditions requiring regular injections. Continued investment in this and similar technologies will likely drive future product offerings and market penetration.

Market expansion is another critical component. Xeris Biopharma is actively working to extend the reach of its current products and explore new therapeutic areas. This includes seeking regulatory approvals in additional geographies and developing new formulations to address unmet medical needs. Successful market expansion will significantly contribute to revenue growth.

Strategic initiatives and partnerships also play a crucial role in Xeris Biopharma's growth trajectory. Collaborations with other pharmaceutical companies, research institutions, or technology providers can accelerate product development, expand market access, and diversify the company's portfolio. These partnerships can provide access to new technologies, funding, and expertise, enhancing Xeris Biopharma's competitive position.

The competitive advantages that position Xeris Biopharma for growth include:

• Proprietary Technology: The XeriJect™ platform and other drug delivery technologies provide a unique selling proposition.
• Focus on Patient Convenience: Ready-to-use formulations offer significant advantages for patients and healthcare providers.
• Strategic Partnerships: Collaborations can accelerate development and expand market reach.

While specific future revenue growth projections and earnings estimates were not available in the provided search snippets, understanding these drivers provides a framework for investors to assess Xeris Biopharma's potential. These factors collectively enhance Xeris Biopharma's prospects for sustained growth and market leadership. More information about the company can be found here: Mission Statement, Vision, & Core Values of Xeris Biopharma Holdings, Inc. (XERS).